

# DYNAVAX

## Dynavax to Present at the H.C. Wainwright Virtual 2021 Global Life Sciences Conference

March 1, 2021

EMERYVILLE, Calif., March 1, 2021 /PRNewswire/ -- [Dynavax Technologies Corporation](#) (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that [Ryan Spencer](#), Chief Executive Officer, will present at the [H.C. Wainwright Virtual 2021 Global Life Sciences Conference](#) being held March 9-10, 2021.

—  
The on demand presentation will be available, beginning Tuesday, March 9, 2021 at 7:00 a.m. E.T. and may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at <http://investors.dynavax.com/events-presentations>.

### About Dynavax

Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. and Europe for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza. For more information, visit [www.dynavax.com](http://www.dynavax.com) and follow the company on [LinkedIn](#).

### Contacts:

Nicole Arndt  
[narndt@dynavax.com](mailto:narndt@dynavax.com)  
510-665-7264

Derek Cole, President  
Investor Relations Advisory Solutions  
[derek.cole@IRadvisory.com](mailto:derek.cole@IRadvisory.com)

 View original content to download multimedia:<http://www.prnewswire.com/news-releases/dynavax-to-present-at-the-hc-wainwright-virtual-2021-global-life-sciences-conference-301237827.html>

SOURCE Dynavax Technologies